Ronald Hoffman

Ronald Hoffman, MD, is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, specializing in Hematology and Medical Oncology. He serves as Director of the Myeloproliferative Disorders Research Program, which he founded in 2007 to address blood cancers like myelofibrosis and essential thrombocythemia.

• MD, New York University School of Medicine
• Residency in Internal Medicine, Montreal General Hospital
• Residency in Internal Medicine, Stanford University School of Medicine
• Fellowship in Hematology, Mount Sinai Hospital

Dr. Hoffman leads translational research in myeloproliferative neoplasms, focusing on hematopoietic stem cells, progenitor cells, and cord blood stem cell expansion for cancer therapies. His work bridges laboratory discoveries with clinical applications.

His recent publications emphasize therapeutic advances in blood cancers, including immunological consequences of stem cell transplantation, genetic markers in myelofibrosis, and updated guidelines for polycythemia vera management. These reflect trends in precision medicine and targeted therapies.

• 2017 Mentor Award from American Society of Hematology

Dr. Hoffman mentors post-doctoral fellows and junior faculty through the Mentoring Committee at Icahn School of Medicine. He spearheads the Myeloproliferative Neoplasm Research Consortium, overseeing multi-institutional clinical trials for novel therapies.

His clinical work centers on myeloproliferative disorders, acute myeloid leukemia, and hematologic malignancies at Mount Sinai’s Tisch Cancer Institute and Atran Berg Laboratory Building.